Effectiveness of Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction Using Real-World Data: An Updated Systematic Review and Meta-Analysis
<p dir="ltr">We conducted a systematic review and meta-analysis to assess all-cause mortality and heart failure (HF) hospitalization with sacubitril/valsartan (S/V) compared to standard HF therapy in patients with <u>HF with reduced ejection fraction </u>(HFrEF) using rea...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , , , , , |
| منشور في: |
2022
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513547399069696 |
|---|---|
| author | Alaa Rahhal (14150403) |
| author2 | Mohamed Kasem (8602740) Bassant Orabi (17269123) Fatima Hamou (17347051) Safae Abuyousef (17347054) Ahmed Mahfouz (737928) Sumaya Alyafei (14147868) Ahmed Emad Shoukry (17347057) Emad Ahmed (440104) |
| author2_role | author author author author author author author author |
| author_facet | Alaa Rahhal (14150403) Mohamed Kasem (8602740) Bassant Orabi (17269123) Fatima Hamou (17347051) Safae Abuyousef (17347054) Ahmed Mahfouz (737928) Sumaya Alyafei (14147868) Ahmed Emad Shoukry (17347057) Emad Ahmed (440104) |
| author_role | author |
| dc.creator.none.fl_str_mv | Alaa Rahhal (14150403) Mohamed Kasem (8602740) Bassant Orabi (17269123) Fatima Hamou (17347051) Safae Abuyousef (17347054) Ahmed Mahfouz (737928) Sumaya Alyafei (14147868) Ahmed Emad Shoukry (17347057) Emad Ahmed (440104) |
| dc.date.none.fl_str_mv | 2022-10-27T18:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1016/j.cpcardiol.2022.101412 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Effectiveness_of_Sacubitril_Valsartan_in_Heart_Failure_with_Reduced_Ejection_Fraction_Using_Real-World_Data_An_Updated_Systematic_Review_and_Meta-Analysis/29126651 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Cardiovascular medicine and haematology Pharmacology and pharmaceutical sciences Health sciences Epidemiology Heart failure (HF) Reduced ejection fraction (HFrEF) Sacubitril/valsartan (S/V) All-cause mortality HF hospitalization |
| dc.title.none.fl_str_mv | Effectiveness of Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction Using Real-World Data: An Updated Systematic Review and Meta-Analysis |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <p dir="ltr">We conducted a systematic review and meta-analysis to assess all-cause mortality and heart failure (HF) hospitalization with sacubitril/valsartan (S/V) compared to standard HF therapy in patients with <u>HF with reduced ejection fraction </u>(HFrEF) using real-world data. We performed a systematic review and meta-analysis following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We searched PubMed and Google Scholar for the observational studies published in English exploring the clinical outcomes of S/V use in HFrEF till March 14, 2022. Two independent reviewers assessed the quality and risk of bias of the included studies. A random-effect model was used to combine data. The outcomes assessed were all-cause mortality and HF hospitalization associated with S/V use in comparison to standard HF therapy. A total of 9 observational studies comparing S/V to Angiotensin-converting enzyme inhibitors (ACE-I)/Angiotensin II receptor blockers (ARB) in HFrEF were included in the systematic review, with more than 32000 patients included in the final analysis. Overall, S/V use was associated with a significant reduction in all-cause mortality (Risk Ratio [RR] = 0.70, 95% CI 0.53-0.93, I<sup>2</sup> = 83%) and HF hospitalization (RR = 0.62; 95% CI, 0.48-0.80, I<sup>2</sup>= 94%). Similar to the landmark controlled evidence, real-world data of S/V use in HFrEF demonstrated a significant reduction in all-cause mortality and HF hospitalization.</p><h2>Other Information</h2><p dir="ltr">Published in: Current Problems in Cardiology<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.cpcardiol.2022.101412" target="_blank">https://dx.doi.org/10.1016/j.cpcardiol.2022.101412</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_cb98da2ed9768c1c96cbbcfde7ee3831 |
| identifier_str_mv | 10.1016/j.cpcardiol.2022.101412 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/29126651 |
| publishDate | 2022 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Effectiveness of Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction Using Real-World Data: An Updated Systematic Review and Meta-AnalysisAlaa Rahhal (14150403)Mohamed Kasem (8602740)Bassant Orabi (17269123)Fatima Hamou (17347051)Safae Abuyousef (17347054)Ahmed Mahfouz (737928)Sumaya Alyafei (14147868)Ahmed Emad Shoukry (17347057)Emad Ahmed (440104)Biomedical and clinical sciencesCardiovascular medicine and haematologyPharmacology and pharmaceutical sciencesHealth sciencesEpidemiologyHeart failure (HF)Reduced ejection fraction (HFrEF)Sacubitril/valsartan (S/V)All-cause mortalityHF hospitalization<p dir="ltr">We conducted a systematic review and meta-analysis to assess all-cause mortality and heart failure (HF) hospitalization with sacubitril/valsartan (S/V) compared to standard HF therapy in patients with <u>HF with reduced ejection fraction </u>(HFrEF) using real-world data. We performed a systematic review and meta-analysis following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We searched PubMed and Google Scholar for the observational studies published in English exploring the clinical outcomes of S/V use in HFrEF till March 14, 2022. Two independent reviewers assessed the quality and risk of bias of the included studies. A random-effect model was used to combine data. The outcomes assessed were all-cause mortality and HF hospitalization associated with S/V use in comparison to standard HF therapy. A total of 9 observational studies comparing S/V to Angiotensin-converting enzyme inhibitors (ACE-I)/Angiotensin II receptor blockers (ARB) in HFrEF were included in the systematic review, with more than 32000 patients included in the final analysis. Overall, S/V use was associated with a significant reduction in all-cause mortality (Risk Ratio [RR] = 0.70, 95% CI 0.53-0.93, I<sup>2</sup> = 83%) and HF hospitalization (RR = 0.62; 95% CI, 0.48-0.80, I<sup>2</sup>= 94%). Similar to the landmark controlled evidence, real-world data of S/V use in HFrEF demonstrated a significant reduction in all-cause mortality and HF hospitalization.</p><h2>Other Information</h2><p dir="ltr">Published in: Current Problems in Cardiology<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.cpcardiol.2022.101412" target="_blank">https://dx.doi.org/10.1016/j.cpcardiol.2022.101412</a></p>2022-10-27T18:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1016/j.cpcardiol.2022.101412https://figshare.com/articles/journal_contribution/Effectiveness_of_Sacubitril_Valsartan_in_Heart_Failure_with_Reduced_Ejection_Fraction_Using_Real-World_Data_An_Updated_Systematic_Review_and_Meta-Analysis/29126651CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/291266512022-10-27T18:00:00Z |
| spellingShingle | Effectiveness of Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction Using Real-World Data: An Updated Systematic Review and Meta-Analysis Alaa Rahhal (14150403) Biomedical and clinical sciences Cardiovascular medicine and haematology Pharmacology and pharmaceutical sciences Health sciences Epidemiology Heart failure (HF) Reduced ejection fraction (HFrEF) Sacubitril/valsartan (S/V) All-cause mortality HF hospitalization |
| status_str | publishedVersion |
| title | Effectiveness of Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction Using Real-World Data: An Updated Systematic Review and Meta-Analysis |
| title_full | Effectiveness of Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction Using Real-World Data: An Updated Systematic Review and Meta-Analysis |
| title_fullStr | Effectiveness of Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction Using Real-World Data: An Updated Systematic Review and Meta-Analysis |
| title_full_unstemmed | Effectiveness of Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction Using Real-World Data: An Updated Systematic Review and Meta-Analysis |
| title_short | Effectiveness of Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction Using Real-World Data: An Updated Systematic Review and Meta-Analysis |
| title_sort | Effectiveness of Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction Using Real-World Data: An Updated Systematic Review and Meta-Analysis |
| topic | Biomedical and clinical sciences Cardiovascular medicine and haematology Pharmacology and pharmaceutical sciences Health sciences Epidemiology Heart failure (HF) Reduced ejection fraction (HFrEF) Sacubitril/valsartan (S/V) All-cause mortality HF hospitalization |